christoph driessen

List of Publications by Year
in descending order

67 papers	5,101 citations	81743 39 h-index	102304 66 g-index
68 all docs	68 docs citations	68 times ranked	6462 citing authors

#	Article	IF	Citations
1	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	0.8	25
2	Complete hematological and major molecular response through treatment with lowâ€dose Interferon alpha 2a in highâ€risk polycythemia vera patient: a case report. Clinical Case Reports (discontinued), 2021, 9, e04903.	0.2	0
3	An inhibitor of proteasome Î²2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Advances, 2018, 2, 2443-2451.	2.5	27
4	Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitorâ€“refractory multiple myeloma. Blood, 2018, 132, 2097-2100.	0.6	27
5	Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica, 2016, 101, 346-355.	1.7	44
6	A Set of Activityâ€Based Probes to Visualize Human (Immuno)proteasome Activities. Angewandte Chemie - International Edition, 2016, 55, 4199-4203.	7.2	86
7	Improved survival of older patients with multiple myeloma in the era of novel agents. Hematological Oncology, 2016, 34, 217-223.	0.8	23
8	The novel Â2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica, 2015, 100, 1350-1360.	1.7	39
9	Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Journal of Clinical Oncology, 2015, 33, 2523-2529.	0.8	157
10	Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Organic and Biomolecular Chemistry, 2015, 13, 5147-5157.	1.5	26
11	The novel Î²2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemotherapy and Pharmacology, 2015, 76, 383-396.	1.1	13
12	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185
13	Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leukemia Research, 2014, 38, 383-392.	0.4	44
14	Cancer-Selective Targeting of the NF-Î°B Survival Pathway with GADD45Î²/MKK7 Inhibitors. Cancer Cell, 2014, 26, 495-508.	7.7	99
15	Structure-Based Design of Î²1i or Î²5i Specific Inhibitors of Human Immunoproteasomes. Journal of Medicinal Chemistry, 2014, 57, 6197-6209.	2.9	89
16	Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides. Cancer Immunology, Immunotherapy, 2013, 62, 715-726.	2.0	6
17	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. European Journal of Cancer, 2013, 49, 290-296.	1.3	74
18	Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites. Journal of Medicinal Chemistry, 2013, 56, 1262-1275.	2.9	79

#	Article	IF	Citations
19	Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. PLoS ONE, 2013, 8, e74415.	1.1	45
20	Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer Journal, 2013, 3, e103-e103.	2.8	43
21	Cathepsin S dominates autoantigen processing in human thymic dendritic cells. Journal of Autoimmunity, 2012, 38, 332-343.	3.0	32
22	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 2011, 118, 4519-4529.	0.6	309
23	Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events. Clinical Cancer Research, 2011, 17, 2734-2743.	3.2	358
24	Intravascular Lymphoma Mimicking Cerebral Stroke: Report of Two Cases. Case Reports in Neurology, 2011, 3, 278-283.	0.3	21
25	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leukemia and Lymphoma, 2010, 51, 2006-2011.	0.6	14
26	Cathepsin G is differentially expressed in primary human antigen-presenting cells. Cellular Immunology, 2009, 255, 41-45.	1.4	28
27	Syringolin A Selectively Labels the 20â€‰S Proteasome in Murine EL4 and Wildâ€Type and Bortezomibâ€Adapted Leukaemic Cell Lines. ChemBioChem, 2009, 10, 2638-2643.	1.3	65
28	Receptorâ€Mediated Targeting of Cathepsins in Professional Antigen Presenting Cells. Angewandte Chemie - International Edition, 2009, 48, 1629-1632.	7.2	35
29	Characterization of the ubiquitinâ€"proteasome system in bortezomib-adapted cells. Leukemia, 2009, 23, 1098-1105.	3.3	125
30	Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer, 2008, 112, 659-670.	2.0	57
31	Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. European Journal of Immunology, 2008, 38, 2401-2411.	1.6	63
32	Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Molecular Cancer Therapeutics, 2008, 7, 1940-1948.	1.9	64
33	Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. British Journal of Radiology, 2008, 81, 386-396.	1.0	39
34	Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood, 2008, 111, 109-111.	0.6	169
35	Human cytomegalovirus infection interferes with major histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels. Journal of General Virology, 2008, 89, 2427-2436.	1.3	16
36	Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins. Journal of Leukocyte Biology, 2007, 81, 990-1001.	1.5	24

#	Article	IF	Citations
37	A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A. Biochemical and Biophysical Research Communications, 2007, 364, 243-249.	1.0	32
38	The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer, 2007, 109, 1617-1626.	2.0	75
39	Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia, 2007, 21, 84-92.	3.3	74
40	Interferon-? regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro. Immunology, 2007, 121, 82-93.	2.0	18
41	A new approach for distinguishing cathepsinâ€ƒE and D activity in antigen-processing organelles. FEBS Journal, 2007, 274, 3138-3149.	2.2	35
42	Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain. Biological Chemistry, 2006, 387, 1503-11.	1.2	23
43	Probing the potential of platinum(II) complexes for the inhibition of thiol-dependent enzymatic activity. Journal of Inorganic Biochemistry, 2005, 99, 1384-1389.	1.5	16
44	Biotinylated fluorescent peptide substrates for the sensitive and specific determination of cathepsin D activity. Journal of Peptide Science, 2005, 11, 166-174.	0.8	16
45	Differential Processing of Autoantigens in Lysosomes from Human Monocyte-Derived and Peripheral Blood Dendritic Cells. Journal of Immunology, 2005, 175, 5940-5949.	0.4	45
46	Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7922-7927.	3.3	573
47	Cathepsin G, and Not the Asparagine-Specific Endoprotease, Controls the Processing of Myelin Basic Protein in Lysosomes from Human B Lymphocytes. Journal of Immunology, 2004, 172, 5495-5503.	0.4	73
48	Development of an isotope-coded activity-based probe for the quantitative profiling of cysteine proteases. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3131-3134.	1.0	31
49	Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner. Journal of Leukocyte Biology, 2004, 75, 844-855.	1.5	30
50	Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. Journal of Neuroimmunology, 2003, 138, 132-143.	1.1	44
51	Activity and subcellular distribution of cathepsins in primary human monocytes. Journal of Leukocyte Biology, 2003, 73, 235-242.	1.5	31
52	Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood, 2003, 101, 420-424.	0.6	145
53	Modulation of the Endosomal and Lysosomal Distribution of Cathepsins B, L and S in Human Monocytes/Macrophages. Biological Chemistry, 2002, 383, 1277-83.	1.2	20
54	Characterization of Legumain. Biological Chemistry, 2002, 383, 1813-1816.	1.2	20

#	Article	IF	Citations
55	Specific role for cathepsin S in the generation of antigenic peptidesin vivo. European Journal of Immunology, 2002, 32, 467-476.	1.6	98
56	Inflammatory stimuli recruit cathepsin activity to late endosomal compartments in human dendritic cells. European Journal of Immunology, 2002, 32, 3348-3357.	1.6	49
57	Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion, 2002, 42, 321-327.	0.8	32
58	Regulation of CD1 Function and NK1.1+ T Cell Selection and Maturation by Cathepsin S. Immunity, 2001, 15, 909-919.	6.6	75
59	Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via FcÎ³ receptors. European Journal of Immunology, 2001, 31, 1592-1601.	1.6	51
60	Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic proteinin vitro. European Journal of Immunology, 2001, 31, 3726-3736.	1.6	94
61	The p41 isoform of invariant chain is a chaperone for cathepsin L. EMBO Journal, 2001, 20, 4055-4064.	3.5	66
62	Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM. EMBO Journal, 2000, 19, 882-891.	3.5	41
63	Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages. Journal of Experimental Medicine, 2000, 191, 1177-1186.	4.2	216
64	Cathepsin S Controls the Trafficking and Maturation of Mhc Class II Molecules in Dendritic Cells. Journal of Cell Biology, 1999, 147, 775-790.	2.3	210
65	Proteases involved in MHC dass II antigen presentation. Immunological Reviews, 1999, 172, 109-120.	2.8	223
66	Stimulation of Human Peripheral Blood Mononuclear Cells by Zinc and Related Cations. Cytokine, 1996, 8, 767-771.	1.4	57
67	Divergent Effects of Zinc on Different Bacterial Pathogenic Agents. Journal of Infectious Diseases, 1995, 171, 486-489.	1.9	38